Enriching case selection for imminent RA: The use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms-a cohort study

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1452-1456

  Nam, Jacqueline L ^a,b   Hunt, Laura ^a,b   Hensor, Elizabeth M A ^a,b   Emery, Paul ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Ant CCP; Autoantibodies; Early Rheumatoid Arthritis; Rheumatoid Arthritis

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; POLYMYOSITIS; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVITIS; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84942133951     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207871     Document Type: Article

References (22)

1. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
2. Demoruelle MK, Parish MC, Derber LA, et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013;65:2243-52.
3. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004;50: 709-15.
4. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005;32:231-8.
5. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
6. Stack RJ, van Tuyl LH, Sloots M, et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: A qualitative exploration of symptom development. Rheumatology (Oxford) 2014;53:1646-53.
7. National Audit Office. Services for people with rheumatoid arthritis. 2009. http://www.nao.org.uk/report/services-for-people-with-rheumatoid-Arthritis/(HC 823 session 2008-2009).
8. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum 2000;43:22-9.
9. van der Linden MP, le Cessie S, Raza K, et al. Long-Term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62:3537-46.
10. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-Tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
11. Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: A prospective observational cohort study. Ann Rheum Dis 2015;74:1659-66.
12. National Institute of Health Research Clinical Research Network. http://www.crn. nihr.ac.uk/
13. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
14. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
15. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007;165:710-18.
16. Jonsson T, Thorsteinsson J, Kolbeinsson A, et al. Population study of the importance of rheumatoid factor isotypes in adults. Ann Rheum Dis 1992;51:863-8.
17. Chibnik LB, Mandl LA, Costenbader KH, et al. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009;36:706-11.
18. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: A prospective cohort study. Ann Rheum Dis 2010;69:490-4.
19. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012;71:638-41.
20. Liang MH, Couto MC, Duarte CC, et al. An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks. Clin Rheumatol 2015;34:465-70.
21. Gao IK, Haas-Wohrle A, Mueller KG, et al. Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Ann Rheum Dis 2005;64:1516-17.
22. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012;64:1756-61.